Tatem Alexander J, Beilan Jonathan, Kovac Jason R, Lipshultz Larry I
Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA.
Men's Health Center, Indianapolis, IN, USA.
World J Mens Health. 2020 Apr;38(2):141-150. doi: 10.5534/wjmh.190002. Epub 2019 Mar 26.
There is often inherent conflict in the overlapping fields of male fertility and andrology. While the goal of all male fertility specialists is to facilitate and preserve biologic paternity, many practitioners also care for a significant number of patients suffering from hypogonadism. Exogenous testosterone administration, the gold standard for the management of these patients, almost universally impairs spermatogenesis and can even completely eradicate it in some men. With steady increases in both the incidence of hypogonadism and average paternal age, practitioners are now encountering hypogonadal men who desire future fertility or men suffering the effects of earlier androgenic anabolic steroid use with increasing frequency. In this manuscript, we review management strategies for these complex patients and explore novel medications that may be of use in this population.
男性生育力与男科学这两个重叠领域常常存在内在冲突。虽然所有男性生育专家的目标都是促进和维持生物学上的父系身份,但许多从业者也会诊治大量性腺功能减退的患者。外源性睾酮给药是这些患者治疗的金标准,但几乎普遍会损害精子发生,甚至在某些男性中可完全消除精子发生。随着性腺功能减退发病率和平均父亲年龄的稳步上升,从业者现在越来越频繁地遇到渴望未来生育的性腺功能减退男性,或遭受早期雄激素合成代谢类固醇使用影响的男性。在本手稿中,我们回顾了这些复杂患者的管理策略,并探索了可能对该人群有用的新型药物。